< Terug naar vorige pagina


The Use of Toll-like Receptor 4 Agonist to Reshape the Immune Signature in Ovarian Cancer

Tijdschriftbijdrage - Tijdschriftartikel

Dendritic cell (DC) mono-immunotherapy has not been successful so far in ovarian cancer. The addition of a toll-like receptor (TLR) agonist has the potential to boost the innate immune system, in addition to the adoptive immune response initiated by DCs.
Tijdschrift: Anticancer Research
ISSN: 0250-7005
Issue: 11
Volume: 36
Pagina's: 5781 - 5792
Jaar van publicatie:2016